2017. ISPOR Latin America Conference – Secukinumab provides greater symptomatic improvement versus adalimumab in psoriatic arthritis: Comparative effectiveness up to 48 weeks assessed by two matching-adjusted indirect comparisons

Thom H, Hunger M, Rosal GF, Gandhi K, Jugl SM, Nash P. Secukinumab provides greater symptomatic improvement versus adalimumab in psoriatic arthritis: Comparative effectiveness up to 48 weeks assessed by two matching-adjusted indirect comparisons. Value Health. 2017 Oct-Nov;20(9):A935. Presented at: ISPOR 6th Latin America Conference 2017; September 15-17, 2017; Sao Paulo, Brazil.